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Suminary
  Previous studies have shown that DMSA (meso-2, 3-dimercaptosuccinic acid, succimer)
and DMPS (2, 3-dimercapto-1-propane sulfonic acid, Na salt, unithiol) are effective anti-
dotes for pentavalent arsenate and trivalent arsenite because they reduce the mortality of
mice poisoned with these arsenic compounds. Studies have also shown that in mice treated
with arsenite, DMPS and DMSA promote excretion of arsenic into the bile and urine, re-
spectively. T[his study was conducted to determine whether DMSA and DMPS promote ar-
senate excretion to the sarne extent as previously reported for arsenite. T[he results demon-
strated that DMPS antagonized arsenate toxicity by improving excretion of arsenic, al-
though to a lesser extent than in studies with arsenite, while DMSA showed a slight but
statistically insignificant promotion of early arsenic excretion in the urine.
Introduction
  DMPS (2, 3-dimercapto-1-propane sulfonic acid, Na salt, unithiol) as well as DMSA (meso-2,3-
dimercaptosuccinic acid, succimer) are promising antidotes for poisoning by heavy metals such as
arsenic, mercury or leadi•2•3,`,5,6). In the US, DMSA has already been approved as a drug of choice
for children suffering from heavy lead poisoning 7}. DMPS, however , has not yet been approved.
  One of the present authors3} previously reported that in experiments using mice, DMPS and
DMSA showed promoted excretion of arsenic into the bile and into the urine, respectively.
  Inorganic arsenic, when given to animals, is biotransformed into organic arsenic compoundsS• 9• iO).
In general, arsenate is first converted to arsenite, then methylated to monomethylarsonate and fur-
ther converted to diemthylarsinate. These biotransformations can be considered as a process of in-
toxication, that is, a conversion to less toxic arsenic compounds in the animal body.
  In acute tests2,`), antagonizing effects of both DMSA and DMPS •against toxicity of arsenic com-
pounds were observed for trivalent arsenic, pentavalent arsenate and monomethylarsonate (in de-
creasing order) in contrast to BAL (dimercaprol) which is an effective antidote for arsenite, but not
for arsenate.
  We examined whether DMSA and DMPS promote arsenate excretion into the mouse urine or feces
to the same extent as previously reported for arsenite3).
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Materials and Methods
  Materials : Sodium arsenate (Na2HAs04) and DMSA were obtained from Nacalai Tesque, Inc.
(Kyoto, Japan), and DMPS from Sigma Chemical Co. (St. Louis, MO). Both sodium arsenate and
DMPS were dissolved in physiological saline. DMSA was dissolved in 59o NaHC03 and diluted with
physiological saline. All solutions were prepared iinmediately before use.
  Animals and treatments : This study was performed according to the grtidelines of our school for
animal experiments. ICR strain male mice were obtained from Japan SLC Inc. (Shizuoka). Tliey
were used at 5 weeks of age, after a week quarantine, weighing 25-30g. The animals were housed in
a temperature--controlled room at 22 Å} 2Åé wi'th a 12 hr light/dark cycle and allowed free access to a
commercial diet (MF, Oriental Yeast Co., Ltd. Tokyo) and distilled water during the study. Tfhe aiii-
mals were divided into three groups of 15 mice, and as three mice were housed together in a one
metabolic cage during the experiment, each group comprised 5 cages. One group was given a single
dose of sodium arsenate (5mg, Aslkg), subcutaneously. Two other groups were given DMSA (100mg/
kg) or DMPS (100 mg/kg) intraperioneally, immediately after subcutaneous administration of the
arsenate (5mg, Aslkg).
  Sample collections and arsenate determination : Urine collections were made at 12hr, 14hr and
48hr after the treatment. Feces were collected at 24hr intervals over 2 days. Arsenate contents in
the urine and feces were determined by atomic absorption spectrometry method. In this methodi'),
since a process of reduction of arsenate into arsenite in the samples was included, al1 arsenic com-
pounds were determined to be trivalent arsenic.
  Statistical methods : Statistical significance was evaluated by Student's t test. Only pSO.05 was
considered significant. Values were expressed as means Å} S.D.
Results
  Table 1 shows arsenic excretion in the urine and feces after a single a(hninistration of sodium ar-
senate with and without DMSA or DMPS in mice.
Table 1 : Urinary and fecal excretion of arsenic after a single a(iministration of sodium arsenate with
        DMSA or DMPS in mice (9e ofdose, Mean Å} S.D.)
[[imeofsamplecollection
Group Sarnple
12hr 24hr 48hr
Totalarsenicin
urineandfeces
arsenatei) Urine
Feces
63.9Å}7.9 1.8Å}3.3
8.8Å}4.6
1.4Å}O.5
O.4Å}O.5
67.1Å}9.7
9.2Å}4.6 76.3Å}9.2
arsenate
and
DMSA2)
Urine
Feces
72.2Å}3.4 O.8Å}O.7
2.2Å}1.5
1.0Å}1.1
O.3Å}O.6
74.0Å}4.0
2.5Å}1.4* 76.5Å}3.4
aesenate
and
DMPs3)
Urine
Feces
73.0Å}5.5 1.8Å}O.6
13.7Å}1.8
1.5Å}2.3
O.1Å}O.1
76.3Å}4.4
13.8Å}1.8 90.1Å}5.7*
1) Sodium arsenate (5mg, Aslkg) was given by subcutaneous injection.
2) DMSA (100mgtkg) was given by jntraperitoneal injection, immediately after the a
  sodium arsenate (5mg, As/kg).
3) DMPS (100mglkg) was given by intraperitoneal injection, immediately after the a
  sodium arsenate (5mg, As/kg).
*p$O.05, significantly different from respective value of arsenate group. N=5.
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  In the first group given only sodium arsenate (5mg, Aslkg, s.c.), 63.9% of the dose was excreted in
the urine within 12hr after the treatment, and 67.19o was observed as cumulative excretion until 48
hr after the administration. Arsenic in the feces was detected as 8.89o of the dose after 24hr and
9.29o within 48hr. Total arsenic excreted through the urine and feces was 76.39o within 48hr.
  In the second group, given sodium arsenate (5mg, As/kg, s.c.) and DMSA (100 mg/kg, i.p.), 72.29o
and 74.09o ofthe dose were excreted in the urine 12hr and 48hr after the treatment, respectively. Al-
though arsenic contents in the urine, collected at 12hr and cumulatively until 48hr after the treat-
ment, exceeded the control value, both of these values were not significantly different from the re-
spective control (the first group) values. But the total amout of arsenic excreted in feces during the
period showed a significant decrease.
  In the third group, given arsenate (5mg, Aslkg, s.c.) and DMPS (100 mglkg, i.p.), 73.09e, 74.89o and
76.39o of the dose were excreted in the urine at 12hr, 24hr and 48 hr after the treatment, respec-
tively. None of these values was statistically significant. Arsenic detected in the feces within 24hr af-
ter the treatment was 13.79o, but this was also not statistically significant. Althouth no statistical
differences were evident, total arsenic excretion rates including urine and feces in the third group
was 90.19o and this was significantly different (pSO.05) from the control value (76.39o).
  Improved excretion of arsenate by the administraion ofDMPS was thus more evident as compared
with DMSA.
Discussion
  Many investigationsi• 2, 3, `, 5, 6) have been reported concerning the effectiveness of DMSA and DMPS
on antagonizing the toxicity ofheavy metals. In the acute toxicity tests in mice2}, both DMSA and
DMPS protected well against inorganic trivalent arsenic poisoning, reducing mortality. Although
the effect in reducing ofmortality in mice poisoned with inorganic pentavalent arsenate was slightly
less than that in the case of the trivalent arsenite, these drugs were considered as usefu1 antagonists
against arsenate as well as arsenite. [I]his is in contrast with BAL which is the only approved anti-
dote for arsenic poisoning in Japan, and which does not reduce the mortality of mice poisoned by
pentavalent arsenate.
  In the present study, arsenic excretion by DMSA in the urine until 12hr after the administration
of arsenate appeared to be improved, although without statistical significance, while values in
DMPS group exceeded the control value of arsenic content in urine collected O-12hr after the ad-
ministration, as well as in feces collected during O-24hr. TEherefore, total arsenic excreted in the
urine and feces within 48hr after the administration in the DMPS group was the most significant
amount among the three groups.
  In this study DMPS appeared to improve the arsenic excretion via feces, presumably through the
bile, in addition to excretion into the urine. In the DMSA group and the control group, the total
amount of arsenic excreted during 48hr after the administration was the same level as about 769o of
the dose, suggesting that 249o of the dose still remained in the body 48hr after the administration.
This contrasts with the case of DMPS where much. greater amout of administered arsenic (more
than 909o) was excreted within 48hr.
  In summary, this study evidenced that DMPS antagonized the arsenate toxicity by improving the
excretion of arsenic, while DMSA appeared to show only a slight promotion of early excretion of ar-
senic in the urine, although without statistical difference.
taJ4swh\ 26(2)•(3) 2000 105
References
1) Aposhian HV (1983) DMSA and DMPS-water soluble antidotes for heavy metal poisoning.
   Annu Rev Pharmacol Toxicol 23 : 193-215.
2) Maehashi H and Murata Y (1983) [Ilreatment of arsenic poisoning with heavy-metal antago-
   nists in mice. Matsumoto Shigaku 9 : 47-51.
3) Maehashi H and Murata Y (1986) Arsenic excretion after treatment of arsenic poisoning with
   DMSA or DMPS in mice. Jpn J Pharmacol 40 : 188-90.
4) Miyazawa T and Maehashi H (1989) The effect of chelating agents on the excretion of sodium
   arsenate and sodium monomethylarsonic acid in mice. Jpn J Pharmacol 49 (suppl) : 336.
5) Aposhian HV (1990) Meso-2,3-dimercaptosuccinic acid : chemical, pharmacological and toxico-
   logical properties ofan orally effective metal chelating agent. Annu Rev Pharmacol Toxicol 30 :
   279-306.
6) Maehashi H, Murata Y and Miyazawa T (1993) Treatment of arsenic poisoning with DMSA or
   DMPS in the rat. Matsumoto Shigaku 19 : 40-4.
7) Richard M, Mariorino, Aposhian MM, Xu ZF, Li Y, Polt RL and Aposhian HV (1993) Determina-
   tion and metabolism of dithiol chelating agents.XV. The meso-2,3-dimercaptosuccinic acid-
   cysteine (1 : 2) mixed disulfide, a major uinary metabolite of DMSA in the human, increases the
   urinary excretion oflead in the rat. J Pharmacol Exp [[her 267 : 1221-6.
8) MeBride BC and Wolfe RS (1971) Biosynthesis of dimethylarsine by methanobagterium. Bio-
   chemistry 10:4312-7.
9) Styblo M, Yamauchi H and Thomas DJ (1995) Comparative in vitro.methylation oftrivalent and
   pentavalent arsenicals. Toxicol Appl Pharmacol 135 : 172-8.
10) Aposhian HV (1997) Enzymatic methylation of arsenic species and other new approaches to ar-
   senic toxicity. Annu Rev Pharmacol Toxicol 37 : 397-419.
11) Ishizaki M (1977) Determination oftotal arsenic in biological samples by flameless atomic ab-
   sorption spectrometry using a carbon tube atomizer. Bunseki Kagaku 26 : 667-72.
?."en : ig:Skta#nrs DMSA h- .k Ue DMPS O) teet F VJ r) Aa)gFJptC:Sst36t?M
                                 ff?Yue}, pkgme E, ntude tk (tzNJIgdiJk•tw5fLPrspt)
 Jts=Sretsrnrs op DMSA (meso-2, 3-dimercatosuccinic acid, succimer) fo' ik as DMPS (2, 3,-di-
mercapto-1-propane sulfonic acid, Na salt, unithiol) Crk t 6 G:ft..,ecÅqD 3 th l: Srk diWPnee g 2) 6t) '(gHA
}:fiEme -g- 6 ShMabS a5 6 t 8 e -g- -(F }:W{i L ti . rk t: .e.,.trit5 }: S 6 kt wa V- F ]J ti A ( 5 fifi e*) e: sc L
"( ts ptExtMrbs'zib D f:. ?l '(fs e wa }- F iJ VA }zv )vts '( S 3Ne aj"e" t Ntwe:VExu{RLffShgehs'zlb 6 rdÅr L" o'
rdieYVXeMVÅr'( as/NC f:. ?oprege, DMPS VStsSeZ12eePSt"(FhOntrp, ts lk ash24eePSrk -(fhOstrp
A•a)eP}lltaghntos'ilb ig , 4sesPÅí t -(fNa)ss,VF}ueig }:JfikoVF?UftmetosLge,.bt) 6 jt'Lk. t iz}:si L'( DMsA re
-i:FOzaE-Vlts512eePdig-(FNdiMrpVEtEteagbngtt6S5-(Fhto.ford}', 48esPMt-(SNOssVFneMCQSJfii E
VS J}k 6 jft. ts thli . fo .
